

Osler, Hoskin & Harcourt LLP
Box 50, 1 First Canadian Place
Toronto, Ontario, Canada M5X 1B8
416.362.2111 MAIN
416.862.6666 FACSIMILE

OSLER

Toronto
Montréal
Ottawa
Calgary
New York

January 25, 2013

Michael Bowman
Direct Dial: (416) 862-6834
mbowman@osler.com
Our Matter Number: 3847159

SENT BY E-MAIL

Chair Peter Milczyn and Members of Planning and Growth Management Committee
City of Toronto
Toronto City Hall
100 Queen Street West
10TH Floor, West Tower
TORONTO, ON M5H 2N2

Attention: Merle MacDonald, Committee Administrator

Dear Chair Milczyn and Members of the Committee:

Applications by Sanofi Pasteur Limited to Amend the Official Plan and Zoning By-law 1755 Steeles Avenue West, Application No.: 10 120978 NNY 10 OZ (the “Applications”)

January 28, 2013 Public Meeting to be held by Planning and Growth Management Committee; Item PG20.3

We are writing on behalf of Sanofi Pasteur Limited (“Sanofi Pasteur”) with respect to the above-referenced Applications for an Official Plan and Zoning By-law Amendment (the “Amendments”) that have been made with respect to its lands located at 1755 Steeles Avenue West (the “Property”). We have also reviewed the December 20, 2012 Report from the Chief Planner and Executive Director, City Planning Division respecting the Applications (the “Staff Report”).

On behalf of Sanofi Pasteur, we wish to enthusiastically endorse the Recommendations contained in the Staff Report. These Recommendations are the culmination of an extensive consultative process undertaken by Sanofi Pasteur with City staff, local residents, commenting agencies and other stakeholders over the past 3 years. If adopted, the Recommendations will facilitate the expansion of Sanofi Pasteur’s vaccine production and research and development activities at the Property, enhancing its position as one of the world’s leading bio-pharmaceutical companies and Toronto’s international role in this growing industry. We therefore request the Committee’s endorsement of these Recommendations.

As set out in the Staff Report, the Amendments are required in order for Sanofi Pasteur to reclaim the southern portion of the Property for employment uses. Although historically owned by Connaught Laboratories Limited, a predecessor company, in the 1970s the

southern portion of the Property was re-designated and rezoned for medium-density residential uses, and a plan of residential subdivision was approved, with necessary land dedications including road allowances made to the former City of North York. However, residential development never took place, and Sanofi Pasteur has now determined that the southern portion of the Property is integral to its long-term plans for its Toronto-based Canadian operations. The Amendments, as described in Recommendations 1 and 2 of the Staff Report, will enable this development of the southern portion of the Property, consistent with the existing planning instruments that apply to the balance of the Property.

Sanofi Pasteur is committed to continuing to work with City staff and other stakeholders to ensure that the remaining Recommendations contained in the Staff Report are successfully implemented. In this regard, Sanofi Pasteur has now executed the Agreement with the City contemplated in Recommendation 5, respecting the purchase of the previously dedicated road allowances for a price of \$900,000. Sanofi Pasteur's lawyers will also be cooperating with the City Solicitor in preparing and submitting the necessary court application under Section 146 of the *Land Titles Act* referenced in Recommendation 4.


The Staff Report has also acknowledged the "robust community consultation process" undertaken by Sanofi Pasteur, including the establishment of a working group consisting of representatives of the local Ratepayers Association, the local councillor and City staff. This consultation process has resulted in modifications to the proposed development that are reflected in draft Official Plan Amendment and draft Zoning By-law Amendment contained in Attachments 6 and 7 of the Staff Report. Sanofi Pasteur remains committed to continuing to engage the local community as development proceeds over the proposed 15 year time horizon.

We have requested the opportunity for Mark Lievonen, President of Sanofi Pasteur, to address the Committee at the January 28, 2013 Public Meeting, to provide additional information about the company's future plans.

Thank you again for your consideration. We will be pleased to answer any questions that arise at the Public Meeting.

Please ensure that we continue to receive all future notices with respect to the Applications.

Yours very truly,

A handwritten signature in black ink, appearing to read "Michael Bowman". The signature is written in a cursive style with a long, sweeping underline that extends to the left.

Michael Bowman
MB:nd